Findings

What do systematic reviews say?

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Xuezhikang vs simvastatin

Serious adverse events · patients with hypercholesterolemia

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 703 participants
GRADE not reported

Xuezhikang vs simvastatin

Cost of care ‐ not reported · patients with hypercholesterolemia

The review found no eligible studies for this question.

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Xuezhikang vs simvastatin

LDL‐cholesterol · patients with hypercholesterolemia

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 885 participants
Very low

Xuezhikang vs simvastatin

HDL‐cholesterol · patients with hypercholesterolemia

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 805 participants
Very low

Xuezhikang vs pravastatin

Cardiovascular events ‐ not reported · patients with hypercholesterolemia

The review found no eligible studies for this question.

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Xuezhikang vs pravastatin

Death from any cause ‐ not reported · patients with hypercholesterolemia

The review found no eligible studies for this question.

1 finding from 1 review

Chinese herbal medicines for hypercholesterolemia 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Morbidity · type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Change in HbA1c from baseline to endpoint % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6308 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1764 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1139 participants
High

Intervention not reported

Change in body weight from baseline to endpoint ‐ Vildagliptin versus placebo kg ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 484 participants
High

Intervention not reported

Adverse events ‐ All‐cause infections ( · patients with type 2 diabetes mellitus

The intervention showed no clear difference in adverse events ‐ All‐cause infections ( (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
RR 1.04 [0.87, 1.24]
10 studies · 3573 participants
High

Intervention not reported

Health‐related quality of life · type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Change in HbA1c from baseline to endpoint % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 6907 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 592 participants
High

Intervention not reported

Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1103 participants
High

Intervention not reported

Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1109 participants
High

Intervention not reported

Adverse events ‐ All‐cause infections ( · type 2 diabetes mellitus

The intervention leads to higher adverse events ‐ All‐cause infections ( (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
RR 1.29 [1.09, 1.52]
8 studies · 3589 participants
High

Intervention not reported

Morbidity · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found